Musculoskeletal embolotherapy (MSK‑ET) is a minimally invasive treatment that reduces chronic pain and inflammation by selectively embolizing abnormal neovessels¹^,². Building on Dr. Yuji Okuno’s pioneering work³, the field has rapidly expanded over the past decade, with growing clinical indications and new embolic technologies⁴.​

neutrals-100

MSK-ET addresses hypervascularity linked to osteoarthritis, overuse or sports-related injuries^1,2,4,5​.

Clinical studies of genicular artery embolization (GAE) for knee osteoarthritis show meaningful improvements in pain and function, while randomized controlled trials, as the gold standard of evidence, play an essential role in further defining and refining the therapy.^6-11​​

Other treatment targets may include:

• Shoulder (e.g. adhesive capsulitis)¹²​
• Hip (e.g. greater trochanteric pain syndrome)^13​
• Foot and ankle (e.g. plantar fasciitis, Achilles tendinopathy)^14-15​
• Elbow (e.g.  lateral epicondylitis a.k.a tennis elbow)^16​
• Other (e.g. temporomandibular joint osteoarthritis, hand/wrist osteoarthritis, patellar tendinopathy, myofascial pain syndromes)^17-20​

neutrals-100

Ideal candidates have chronic pain unresponsive to conservative therapy and imaging evidence of abnormal hypervascularity correlating with symptoms. ​

neutrals-100

Technical success depends on precise navigation into small, tortuous branches supplying the pain generator. This requires microcatheters of exceptional trackability, with versatile tip shapes for selective access to challenging branches. Combined with a stable guiding system, this enables accurate positioning and controlled embolic delivery, minimizing the risk of non-target embolization.​

neutrals-100

Protocols may use either temporary or permanent embolics, with optimal options currently under evaluation. The choice ultimately depends on operator discretion.

neutrals-100